It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The function of MR1-restricted mucosal-associated invariant T (MAIT) cells in tumor immunity is unclear. Here we show that MAIT cell-deficient mice have enhanced NK cell-dependent control of metastatic B16F10 tumor growth relative to control mice. Analyses of this interplay in human tumor samples reveal that high expression of a MAIT cell gene signature negatively impacts the prognostic significance of NK cells. Paradoxically, pre-pulsing tumors with MAIT cell antigens, or activating MAIT cells in vivo, enhances anti-tumor immunity in B16F10 and E0771 mouse tumor models, including in the context of established metastasis. These effects are associated with enhanced NK cell responses and increased expression of both IFN-γ-dependent and inflammatory genes in NK cells. Importantly, activated human MAIT cells also promote the function of NK cells isolated from patient tumor samples. Our results thus describe an activation-dependent, MAIT cell-mediated regulation of NK cells, and suggest a potential therapeutic avenue for cancer treatment.
Mucosal-associated invariant T (MAIT) cells facilitate anti-microbial responses, but their functions in cancer protection is unclear. Here the authors show that activated MAIT cells induce an IFN-γ transcriptome in natural killer (NK) cells and enhance NK-dependent anti-cancer immunity in mice, thereby hinting a new avenue for cancer therapy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
















1 Peter MacCallum Cancer Centre, Cancer Immunology Program, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); The University of Melbourne, Sir Peter MacCallum Department of Oncology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
2 University of Melbourne, Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); University of Melbourne, Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
3 Peter MacCallum Cancer Centre, Cancer Immunology Program, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); The University of Melbourne, Sir Peter MacCallum Department of Oncology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Peter MacCallum Cancer Centre, Tumour Suppression and Cancer Sex Disparity Laboratory, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434)
4 The University of Melbourne, Sir Peter MacCallum Department of Oncology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Peter MacCallum Cancer Centre, Bioinformatics Core Facility, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434)
5 The University of Queensland, Institute for Molecular Bioscience, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); The University of Queensland, Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
6 University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
7 University of Melbourne, Department of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Walter and Eliza Hall Institute of Medical Research, Division of Molecular Immunology, Melbourne, Australia (GRID:grid.1042.7); Monash University, Biomedicine Discovery Institute and the Department of Biochemistry and Molecular Biology, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
8 University of Melbourne, Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
9 Peter MacCallum Cancer Centre, Cancer Immunology Program, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); The University of Melbourne, Sir Peter MacCallum Department of Oncology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Monash University, Department of Immunology, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
10 Peter MacCallum Cancer Centre, Cancer Immunology Program, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); The University of Melbourne, Sir Peter MacCallum Department of Oncology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); University of Melbourne, Department of Pathology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
11 Peter MacCallum Cancer Centre, Cancer Immunology Program, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); The University of Melbourne, Sir Peter MacCallum Department of Oncology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Monash University, Biomedicine Discovery Institute and the Department of Biochemistry and Molecular Biology, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); University of Melbourne, Department of Pathology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)